C-Path is a public/private partnership funded by government agencies such as the *FDA, grants from foundations such as the Bill & Melinda Gates Foundation, Michael J. Fox Foundation and the Polycystic Kidney Disease Foundation, as well as fees from industry participants.
*Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 55% funded by the FDA/HHS, totaling $17,612,250, and 45% funded by non-government source(s), totaling $14,203,111. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. Each perform program work through consortia and separate initiatives. These are:
- Biomarker Data Repository
- Critical Path for Alzheimer’s Disease
- Critical Path for Sickle Cell Disease
- Critical Path for Parkinson’s
- Critical Path to TB Drug Regimens
- Critical Path to Therapeutics for the Ataxias
- Cure Drug Repurposing Collaboratory
- Data Collaboration Center
- Duchenne Regulatory Science Consortium
- Electronic Clinical Outcome Assessment Consortium
- Friedreich’s Ataxia Integrated Database
- Huntington’s Disease Regulatory Science Consortium
- International Neonatal Consortium
- Multiple Sclerosis Outcome Assessments Consortium
- Patient-Reported Outcome Consortium
- PredicTox Knowledge Environment
- Polycystic Kidney Disease Outcomes Consortium
- Predictive Safety Testing Consortium
- Rare Disease Cures Accelerator-Data and Analytics Platform
- TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS)
- Transplant Therapeutics Consortium
- Trial Outcome Markers Initiative in T1D Consortium
- Type 1 Diabetes Consortium
C-Path’s collaborations advance the generation of actionable solutions that help transform the drug development process for the following indications:
- Alzheimer’s disease
- Asthma
- Ataxias, including Friedreich’s Ataxia
- Depression
- Duchenne Muscular Dystrophy
- Functional Dyspepsia
- Huntington’s Disease
- Irritable Bowel Syndrome
- Multiple Sclerosis
- Non-Small Cell Lung Cancer
- Organ Transplant
- Parkinson’s Disease
- Polycystic Kidney Disease
- Rare Diseases
- Rheumatoid Arthritis
- Tuberculosis
- Type 1 Diabetes
They also have expertise in the following:
- Biomarker qualification
- Clinical outcome assessment qualification
- Clinical trial simulation tools
- Data collaboration
- Data standards development
- Database and data repository management
- Drug repurposing
- Drug safety and drug testing
- Evidentiary considerations for biomarker qualification
- Patient-reported outcomes and electronic patient-reported outcomes
- Quantitative medicine – modeling and simulation
- Regulatory science
Please visit our Core Competencies page for more information.
Our IRS Form 990 can be found at GuideStar.org.
To obtain printed copies of our audited financial statements or if you have any questions, please contact us at info@c-path.org.
Click here to view our list of annual reports.